Crisantaspase

Drug Profile

Crisantaspase

Alternative Names: E. chrisanthemi L-asparaginase - EUSA; Asparaginase Erwinia chrysanthemi; Erwina chrisanthemi L-asparaginase; Erwinase; Erwinaze; Erwinia asparaginase; Erwinia L-asparaginase - EUSA; OP-01

Latest Information Update: 10 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Health Protection Agency
  • Developer EUSA Pharma; Jazz Pharmaceuticals plc; Ohara Pharmaceutical
  • Class Amidohydrolases; Cytostatics
  • Mechanism of Action Amidohydrolase stimulants; Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia
  • Registered Lymphoma

Most Recent Events

  • 19 Dec 2016 Registered for Acute lymphoblastic leukaemia in Japan (IM)
  • 19 Dec 2016 Registered for Lymphoma in Japan (IM)
  • 22 Feb 2016 Jazz Pharmaceuticals has protection for Erwinase®, through orphan drug exclusivity, in USA (Jazz Pharmaceuticals, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top